

6th September, 2006

Press Release

The Genetics Company Inc. enters distributorship agreement with EUROMEDEX

The Genetics Company Inc., a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer, is pleased to announce the closing of a distributorship agreement with EUROMEDEX, a leading French wholesaler of research reagents and pharmaceuticals. Within the scope of this agreement, The Genetics Company will supply EUROMEDEX with its innovative beta-Amyloid (A β) detection tools for the diagnosis and research of neurodegenerative diseases, such as Alzheimer's disease and stroke, for distribution in France.

Please find enclosed our press release. Thank you for your consideration and kind regards,



Dr. Harald Eistetter, CEO
eistetter@the-genetics.com

www.the-genetics.com

PRESS RELEASE

Zurich, Switzerland – 6th September, 2006

The Genetics Company Inc. enters distributorship agreement with EUROMEDEX

The Genetics Company Inc., a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer, is pleased to announce the closing of a distributorship agreement with EUROMEDEX, a leading French wholesaler of research reagents and pharmaceuticals. Within the scope of this agreement, The Genetics Company will supply EUROMEDEX with its innovative beta-Amyloid (A β) detection tools for diagnosis and research of neurodegenerative diseases, such as Alzheimer's disease and stroke, for distribution in France.

The Genetics Company's diagnostic and research tools enable the specific and selective detection of variants of human beta-Amyloid (A β), a key protein involved in the pathogenesis of several neurodegenerative diseases. The Company's products include very sensitive and reliable enzyme-linked immunosorbent assay (ELISA)-based test kits for the quantification of A β 40 and A β 42 in either cerebrospinal fluid (CSF) or plasma and cell lysate samples. While the corresponding A β 42/40 ratio has been validated by several recent studies as a superior biomarker for the diagnosis of incipient AD, the Company's test kits are also successfully used in clinical trials as drug monitoring tools or for pre-clinical research and development of A β lowering drugs. In addition, The Genetics Company's portfolio of A β -quantifying tools is complemented by highly selective monoclonal antibodies for the detection of A β , in particular A β 40 and A β 42.

Micheline Azogui, Product Manager of EUROMEDEX said: "The Genetics Company's innovative diagnostic and research tools, which already have gained an excellent reputation in France, perfectly fit into our portfolio of top quality scientific products." Dr. Sebastian Breuer, Program Manager Diagnostics at The Genetics Company added: "We are very pleased with EUROMEDEX, an evident expert in the French life science reagents market and our ideal partner for the further expansion of our business in France."

About Euromedex

EUROMEDEX was established in 1984 as an international pharmaceutical and scientific wholesaler. Headquartered in Strasbourg, France, EUROMEDEX distributes more than 100'000 reagents for immunology, cell biology, molecular biology and genetics in the life sciences field. EUROMEDEX is a central pharmacy and a distribution centre for clinical trials, managing the whole chain of supplies. EUROMEDEX has more than 200'000 pharmaceuticals, medical devices, dietetics, diagnostics and health products available. Through its representative office, EUROMEDEX is a subcontractor for pharmaceutical manufacturers in marketing, regulatory affairs, registration, promotion, export and distribution.

About The Genetics Company, Inc.

The Genetics Company, Inc. is a dedicated team of entrepreneurs and scientists focusing on the research, development and commercialization of innovative products for the diagnosis, therapy and therapy monitoring of patients suffering from neurodegenerative disease and cancer. Apart from a set of worldwide unique diagnostic kits and tools for the diagnosis and monitoring of patients suffering from Alzheimer's disease (AD), the Company has identified small molecule inhibitors of BACE (beta-Amyloid converting enzyme). It has also identified small molecule inhibitors of two proprietary targets within the Wnt-pathway, which is believed to play a crucial role in colon cancer. Headquartered in Zurich-Schlieren, Switzerland, the Company currently has 25 employees.

For additional information about EUROMEDEX please contact:

*Micheline Azogui
EUROMEDEX
Rue des Tuileries, 24
B.P. 74684 Souffelweyersheim
France
Tel: +33-388-180720
Fax: +33-388-180725
E-mail: info@euromedex.com
Web: www.euromedex.com*

For corporate information about The Genetics Company please contact:

*Dr. Harald Eistetter
The Genetics Company
Wagistrasse 27
CH-8952 Schlieren/Zürich
Switzerland
Tel: +41-44-2002222
Fax: +41-44-2002211
E-mail: eistetter@the-genetics.com
Web: www.the-genetics.com*

For further information about The Genetics Company's products please contact:

*Oliver Wildanger
The Genetics Company
Tel: +41-44-2002266
Fax: +41-44-2002211
E-mail: wild@the-genetics.com*